YESPending Review90% confidenceGrok 4.20 (xAI)
Question
Will this trial meet its primary endpoint?
Found
Outcome Date
Summary
ADAPT OCULUS (NCT06558279) topline results show it met primary endpoint: statistically significant MGII ocular PRO improvement vs placebo (p=0.012). Sources frame as positive.
Sources
Sponsorargenx.com
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
ADAPT OCULUS met primary endpoint (p=0.012), with statistically significant improvement in MGII PRO ocular scores at Week 4 vs placebo (4.04 vs 1.99 point change).
Web Searchneurologylive.com
Efgartigimod Meets Primary End Point in Phase 3 ADAPT OCULUS Study in Ocular Myasthenia Gravis
ADAPT OCULUS met its primary endpoint, with efgartigimod producing statistically significant week-4 improvement in MGII ocular score vs placebo (P=0.012).